The 21st Century Cures Act provides significant funding for scientific and medical research to promote innovation that speeds development of treatments for cancer and similar devastating diseases. Many such innovations, like using real-world evidence and patient-centered drug development, themselves require innovation in how data is collected and analyzed as scientific and regulatory evidence.
In this podcast, Deputy Director for the Duke Margolis Center for Health Policy Dr. Gregory Daniel shares his expert perspective on the role that statisticians will play in advancing these initiatives. A Senior Advisor to the Reagan-Udall Foundation for the FDA, Dr. Daniel will also be a featured speaker at DIA’s Annual Statistics Forum. “What FDA really needs is to engage with statisticians within FDA but also outside of FDA, to better understand these statistical techniques, establish best practices for them, and how to ensure that their results are valid and reliable,” he explains.
Listen to the Podcast